Astrana Health (ASTH) Competitors

Globant (NYSE:GLOB) and Astrana Health (NASDAQ:ASTH) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.

Which has more volatility and risk, GLOB or ASTH?

Globant has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Astrana Health has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.

Do analysts rate GLOB or ASTH?

Globant currently has a consensus target price of $219.71, suggesting a potential upside of 69.54%. Astrana Health has a consensus target price of $56.17, suggesting a potential upside of 82.42%. Given Astrana Health's stronger consensus rating and higher probable upside, analysts plainly believe Astrana Health is more favorable than Globant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globant	0 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89

Which has better valuation and earnings, GLOB or ASTH?

Globant has higher revenue and earnings than Astrana Health. Astrana Health is trading at a lower price-to-earnings ratio than Globant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globant	$2.42B	2.36	$158.54M	$3.72	34.84
Astrana Health	$2.03B	0.76	$60.72M	$0.89	34.60

Does the media favor GLOB or ASTH?

In the previous week, Astrana Health had 1 more articles in the media than Globant. MarketBeat recorded 9 mentions for Astrana Health and 8 mentions for Globant. Globant's average media sentiment score of 0.84 beat Astrana Health's score of 0.83 indicating that Globant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globant	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrana Health	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in GLOB or ASTH?

Globant received 378 more outperform votes than Astrana Health when rated by MarketBeat users. However, 84.21% of users gave Astrana Health an outperform vote while only 59.97% of users gave Globant an outperform vote.

Company	Underperform	Outperform
Globant	Outperform Votes 394 59.97%	Underperform Votes 263 40.03%
Astrana Health	Outperform Votes 16 84.21%	Underperform Votes 3 15.79%

Is GLOB or ASTH more profitable?

Globant has a net margin of 6.86% compared to Astrana Health's net margin of 3.63%. Globant's return on equity of 11.83% beat Astrana Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globant	6.86%	11.83%	8.09%
Astrana Health	3.63%	9.37%	5.32%

Do insiders & institutionals have more ownership in GLOB or ASTH?

91.6% of Globant shares are owned by institutional investors. Comparatively, 52.8% of Astrana Health shares are owned by institutional investors. 2.7% of Globant shares are owned by company insiders. Comparatively, 8.5% of Astrana Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Globant beats Astrana Health on 13 of the 19 factors compared between the two stocks.